Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 16-8023 | Other Identifier | Fox Chase Cancer Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary Objective
To assess the feasibility of activity tracking using Fitbit device in terms of compliance (defined as at least 75% of patients complying with instructions to wear the device, for at least 12 hours a day on at least 3 of the 4 assigned days) in patients undergoing therapy for localized and advanced colorectal cancer.
Secondary Objectives
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Rate of usage | To assess the feasibility of activity tracking using Fitbit device in terms of compliance (defined as at least 75% of patients complying with instructions to wear the device, for at least 12 hours a day on at least 3 of the 4 assigned days) in patients undergoing therapy for localized and advanced colorectal cancer. | 4 days |
| Steps | tracker assessed step count | enrollment to 7 days |
Not provided
Not provided
Inclusion Criteria:
Age 18 years or older
Have histologically confirmed colorectal adenocarcinoma (Stage II-IV)
Have an estimated life expectancy of greater than 3 months
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Should meet the following treatment arms:
Able to participate in some degree of physical activity (i.e. walking)
Are undergoing treatment for their cancer at FCCC
Ability to understand and willingness to sign a written informed consent and HIPAA consent
Exclusion Criteria:
No concern
Not provided
Patients with colorectal cancer undergoing chemotherapy
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33492994 | Result | Ward WH, Meeker CR, Handorf E, Hill MV, Einarson M, Alpaugh RK, Holden TL, Astsaturov I, Denlinger CS, Hall MJ, Reddy SS, Sigurdson ER, Dotan E, Zibelman M, Meyer JE, Farma JM, Vijayvergia N. Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer. JCO Clin Cancer Inform. 2021 Jan;5:125-133. doi: 10.1200/CCI.20.00117. |
Not provided
Not provided
At reasonable request to PI
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015179 | Colorectal Neoplasms |
| D004194 | Disease |
| ID | Term |
|---|---|
| D007414 | Intestinal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood and serum frozen and stored
| D009369 | Neoplasms |
| D004066 | Digestive System Diseases |
| D005767 | Gastrointestinal Diseases |
| D003108 | Colonic Diseases |
| D007410 | Intestinal Diseases |
| D012002 | Rectal Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |